Evaluating the impact of microarray pharmacogenetic testing in cancer patients
Evaluating the Use of Microarray Pharmacogenetic Testing in Patients With Cancer
This study is testing if a special genetic test can help doctors choose the right cancer drugs and doses for adults getting chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Charlotte, North Carolina) |
| Trial ID | NCT06489041 on ClinicalTrials.gov |
What this trial studies
This research evaluates how a microarray pharmacogenetic test influences drug prescribing and dosing for cancer patients eligible for single-gene DPYD testing. The study involves adults aged 18 and older who are receiving or will receive fluoropyrimidine-based chemotherapy. Participants will undergo pharmacogenomic testing, and results will be integrated into their electronic medical records. The study will track prescription changes and actions taken based on drug-gene interactions over a six-month period.
Who should consider this trial
Good fit: Ideal candidates are adults 18 years and older who are eligible for standard of care single-gene DPYD testing and are receiving fluoropyrimidine-based chemotherapy.
Not a fit: Patients with a history of prior allogeneic hematopoietic cell transplantation or liver transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective cancer treatment by optimizing drug dosing based on genetic information.
How similar studies have performed: Other studies have shown promise in using pharmacogenetic testing to improve treatment outcomes in cancer patients, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. * Age ≥ 18 years at the time of consent. * Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available. * Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing. Exclusion Criteria: • History of prior allogeneic hematopoietic cell transplantation or liver transplantation
Where this trial is running
Charlotte, North Carolina
- Atrium Health Levine Cancer — Charlotte, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Jai Patel, PharmD — Atrium Health Levine Cancer
- Study coordinator: Megan Lattanze
- Email: Megan.Lattanze@advocatehealth.org
- Phone: (980) 442-4239
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.